Posts Tagged ‘ oversight ’

Reauthorized FDA House Legislation Relaxes Reporting of Medical Device Malfunctions

Reauthorized FDA House Legislation Relaxes Reporting of Medical Device Malfunctions

On July 12, 2017, the U.S. House of Representatives passed, with unusually strong levels of bipartisan support, H.R. 2430 – the FDA Reauthorization Act of 2017. The bill reauthorizes the FDA to collect fees from various medical device manufacturers but changes critical drug and device testing rules. The previous bill upon which H.R. 2430...

Read more »